SPOTLIGHT: Problems with Zantac, Tagamet?

Post-marketing studies can be dangerous: New research published in this month's Journal of the American Geriatrics Society shows that histamine-2 blockers such as Zantac and Tagamet may cause cognitive decline. The five-year study found that 34 percent of participants who used H2 blockers regularly showed a decline in mention functions such as language, memory, and reasoning. The study population was limited to African-Americans 65 and older, so there's hope the results won't be duplicated in other age and ethnic groups. We'll see in a few years; these researchers plan to go back to the drawing board to study just that. Report 

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

The new Community trial will first test Amgen's Otezla, Takeda's Takhzyro and UCB's zilucoplan in hospitalized patients.

Indivior faces a new lawsuit from RB, its former parent company, over a scheme to market opioid addiction therapy Suboxone Film.

A new FDA effort brings cancer drug labels to life in videotaped panels with experts, debuting its first episode on Seagen's MBC med Tukysa.